Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PEPD | P12955 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | LDHB | P07195 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL28263622 | 1.00 | BLM (0.39) | BLMTDP1MEN1LMNAHPGD | |
| Oxalic Acid SCHEMBL28263619 | 1.00 | BLM (0.39) | BLMTDP1MEN1LMNAHPGD | |
| Oxalic Acid SCHEMBL1573557 | 0.95 | BLM (0.41) | BLMTDP1MEN1LMNAHPGD | |
| Oxalic Acid SCHEMBL1574651 | 0.95 | BLM (0.41) | BLMTDP1MEN1LMNAHPGD | |
| Oxalic Acid SCHEMBL7055254 | 0.95 | BLM (0.41) | BLMTDP1MEN1LMNAHPGD | |
| Oxalic Acid SCHEMBL25429376 | 0.91 | BLM (0.39) | BLMTDP1MEN1LMNAHPGD | |
| Oxalic Acid SCHEMBL3463230 | 0.91 | BLM (0.39) | BLMTDP1MEN1LMNAHPGD | |
| Oxalic Acid SCHEMBL9500409 | 0.91 | BLM (0.39) | BLMTDP1MEN1LMNAHPGD | |
| Oxalic Acid SCHEMBL7004785 | 0.91 | BLM (0.39) | BLMTDP1MEN1LMNAHPGD | |
| Oxalic Acid SCHEMBL20817492 | 0.91 | BLM (0.39) | BLMTDP1MEN1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4284384-B1 | CLINICAL DOSING SCHEDULE OF INS-3001 | VIFOR INT AG (CH) | 2026-03-25 | — | — | EP | claimed |
| US-20240100074-A1 | Clinical Dosing Schedule of Inositol Phosphate Oligo(Ethylene Glycol) Compounds | VIFOR (INTERNATIONAL) AG (CH) | 2024-03-28 | — | — | US | claimed |
| US-20240000811-A1 | INOSITOL HEXAKISPHOSPHATE ANALOGUES FOR TREATMENT OF CALCIFICATION ASSOCIATED KIDNEY DISEASES | VIFOR (INTERNATIONAL) AG (CH) | 2024-01-04 | — | — | US | claimed |
| EP-4284384-A1 | CLINICAL DOSING SCHEDULE OF INOSITOL PHOSPHATE OLIGO(ETHYLENE GLYCOL) COMPOUNDS | Vifor (International) AG (CH) | 2023-12-06 | — | — | EP | claimed |
| EP-4247388-A1 | INOSITOL HEXAKISPHOSPHATE ANALOGUES FOR TREATMENT OF CALCIFICATION ASSOCIATED KIDNEY DISEASES | VIFOR (INTERNATIONAL) AG (CH) | 2023-09-27 | — | — | EP | claimed |
| US-11707470-B2 | Inositol derivatives for use in pathological crystallization | ETH ZURICH (CH) | 2023-07-25 | — | — | US | claimed |
| WO-2022161980-A1 | CLINICAL DOSING SCHEDULE OF INOSITOL PHOSPHATE OLIGO(ETHYLENE GLYCOL) COMPOUNDS | INOSITEC AG (CH) | 2022-08-04 | — | — | WO | claimed |
| WO-2022106657-A1 | INOSITOL HEXAKISPHOSPHATE ANALOGUES FOR TREATMENT OF CALCIFICATION ASSOCIATED KIDNEY DISEASES | INOSITEC AG (CH) | 2022-05-27 | — | — | WO | claimed |
| US-11207365-B2 | Combined preparations of urinary acidifiers and crystallization inhibitors and application thereof for the treatment or prevention of phosphatic or calcium phosphate-induced renal lithiasis | UNIVERSITAT DE LES ILLES BALEARS (ES) | 2021-12-28 | — | — | US | claimed |
| US-20210290643-A1 | INOSITOL DERIVATIVES FOR USE IN PATHOLOGICAL CRYSTALLIZATION | ETH ZURICH (CH) | 2021-09-23 | — | — | US | claimed |
| US-20190216873-A1 | COMBINED PREPARATIONS OF URINARY ACIDIFIERS AND CRYSTALLIZATION INHIBITORS AND APPLICATION THEREOF FOR THE TREATMENT OR PREVENTION OF PHOSPHATIC OR CALCIUM PHOSPHATE-INDUCED RENAL LITHIASIS | UNIV ILLES BALEARS (ES) | 2019-07-18 | — | — | US | claimed |
| US-20170106032-A1 | COMBINATION OF A URINARY ACIDIFIER AND A CALCIUM PHOSPHATE CRYSTALLISATION INHIBITOR FOR THE TREATMENT OR PREVENTION OF RENAL LITHIASIS | UNIVERSITAT DE LES ILLES BALEARS (ES) | 2017-04-20 | — | — | US | claimed |
| EP-3130352-A1 | COMBINATION OF A URINARY ACIDIFIER AND A CALCIUM PHOSPHATE CRYSTALLISATION INHIBITOR FOR THE TREATMENT OR PREVENTION OF RENAL LITHIASIS | Universitat de les Illes Balears (ES) | 2017-02-15 | — | — | EP | claimed |
| US-20240329202-A1 | SYSTEMS AND METHODS FOR CONTROLLING LASER TREATMENTS USING REFLECTED INTENSITY SIGNALS | IPG PHOTONICS CORPORATION (US) | 2024-10-03 | — | — | US | disclosed |
| US-20240100074-A1 | Clinical Dosing Schedule of Inositol Phosphate Oligo(Ethylene Glycol) Compounds | VIFOR (INTERNATIONAL) AG (CH) | 2024-03-28 | — | — | US | disclosed |
| US-20240016543-A1 | SYSTEMS AND METHODS FOR CONTROLLING LASER TREATMENTS | IPG PHOTONICS CORPORATION (US) | 2024-01-18 | — | — | US | disclosed |
| EP-3130352-A1 | COMBINATION OF A URINARY ACIDIFIER AND A CALCIUM PHOSPHATE CRYSTALLISATION INHIBITOR FOR THE TREATMENT OR PREVENTION OF RENAL LITHIASIS | Universitat de les Illes Balears (ES) | 2017-02-15 | — | — | EP | disclosed |
| CN-106232143-A | Combined preparation of uricating agent and crystallization inhibitor and application thereof in treating or preventing phosphate or calcium phosphate induced kidney stones | 巴利阿里群岛大学 | 2016-12-14 | — | — | CN | disclosed |
| EP-0889326-B1 | PROCESS FOR EVALUATING THE GLOBAL CAPACITY OF URINE TO FORM CALCIC RENAL CALCULUS, AND CORRESPONDING KIT | UNIV DE LAS ISLAS BALEARES (ES) | 2002-11-13 | — | — | EP | disclosed |
| EP-0889326-A1 | PROCESS FOR EVALUATING THE GLOBAL CAPACITY OF URINE TO FORM CHALKY RENAL CALCULUS, AND CORRESPONDING KIT | Universidad de las Islas Baleares (ES) | 1999-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11207365-B2 | Combined preparations of urinary acidifiers and crystallization inhibitors and application thereof for the treatment or prevention of phosphatic or calcium phosphate-induced renal lithiasis | CA2, ATP6V1B1, ACP3 | BLM 4355/4885TDP1 4606/4885MEN1 2912/4885 |
| US-20190216873-A1 | COMBINED PREPARATIONS OF URINARY ACIDIFIERS AND CRYSTALLIZATION INHIBITORS AND APPLICATION THEREOF FOR THE TREATMENT OR PREVENTION OF PHOSPHATIC OR CALCIUM PHOSPHATE-INDUCED RENAL LITHIASIS | CA2, ATP6V1B1, ACP3 | BLM 4355/4885TDP1 4606/4885MEN1 2912/4885 |
| US-20170106032-A1 | COMBINATION OF A URINARY ACIDIFIER AND A CALCIUM PHOSPHATE CRYSTALLISATION INHIBITOR FOR THE TREATMENT OR PREVENTION OF RENAL LITHIASIS | CA2, ATP6V1B1, CA4 | BLM 4126/4885TDP1 4515/4885MEN1 3259/4885 |
| US-20240000811-A1 | INOSITOL HEXAKISPHOSPHATE ANALOGUES FOR TREATMENT OF CALCIFICATION ASSOCIATED KIDNEY DISEASES | PPIP5K2, INPP5B, IP6K3 | BLM 3823/4885TDP1 3763/4885MEN1 1413/4885 |
| US-20240100074-A1 | Clinical Dosing Schedule of Inositol Phosphate Oligo(Ethylene Glycol) Compounds | PPIP5K2, IPMK, INPP5B | BLM 1619/4885TDP1 707/4885MEN1 504/4885 |
| US-11707470-B2 | Inositol derivatives for use in pathological crystallization | ITPR3, PPIP5K2, ITPR2 | BLM 2868/4885TDP1 1478/4885MEN1 1776/4885 |
| US-20210290643-A1 | INOSITOL DERIVATIVES FOR USE IN PATHOLOGICAL CRYSTALLIZATION | ITPR3, PPIP5K2, ITPR2 | BLM 2868/4885TDP1 1478/4885MEN1 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.